Cornell team uses microfluidic technology to study prostate cancer
A cornell team comprising Paraskevi Giannakakou (Pharmacology, Weill Cornell Medical College), Brian Kirby (Mechanical Engineering, Cornell University), and David Nanus (Hematology/Oncology, Weill Cornell Medical College) is using microfluidic technology to study prostate cancer cells isolated from blood samples. Supported by recent grants awarded by NYSTAR’s Center for Advanced Technology and the Clinical and Translational Science Center, this work uses microfluidic devices to isolate prostate cancer cells, and informs ongoing research into mechanisms and effectiveness of taxane chemotherapy in metastatic prostate cancer patients.